GLP-1– tag –
-
GLP-1 Receptor Agonist Mechanism of Action: A Comprehensive Approach to Glycemic Control, Weight Loss, and Metabolic Health
(Document via Google Search) Overview GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs that mimic incretin action to manage blood sugar and promote weight loss. They stimulate insulin secretion, suppress glucagon production, and ... -
Eli Lilly’s Oral GLP-1 Agonist ‘Foundayo (orforglipron)’ Receives FDA Approval for Obesity and Overweight Treatment
Drugs.com USA Overview Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, has received FDA approval for adults with obesity or certain weight-related conditions. This small-molecule, non-peptide GLP-1 receptor... -
Nagoya University and Fujifilm Jointly Develop Novel LNP Delivery System for Enhanced Cyclic RNA Therapeutics
EurekAlert! Japan Overview Researchers from Nagoya University and Fujifilm have jointly developed a novel lipid nanoparticle (LNP) delivery system designed for efficient and stable intracellular delivery of circular RNA (cirRNA), a promi... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin... -
Entera Bio’s Oral Peptide Platform Advances to Phase 3 for Osteoporosis, Heralding a New Era for Injectable Therapeutics
Entera Bio, Inc. USA Overview Clinical-stage biopharmaceutical company Entera Bio has secured an agreement with the FDA to initiate a Phase 3 clinical trial for EB613, an oral parathyroid hormone (PTH) analog for postmenopausal osteoporo... -
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap... -
GLP-1 Agonist Tirzepatide Significantly Reduces Cardiovascular Events and Infection Risk by One-Third in Type 2 Diabetes and Obesity Patients
Technical University of Munich Germany Overview A study published in The BMJ, conducted by researchers from the Technical University of Munich and Harvard Medical School, found that tirzepatide (Mounjaro), a GLP-1 agonist, significantly ... -
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Boehringer Ingelheim Initiates Phase II for BI 3034701, a Novel GLP-1/GIP/NPY2 Triple Agonist, Reshaping Obesity Treatment
Life Science Daily News USA Overview Boehringer Ingelheim initiated a Phase II trial in July 2026 for BI 3034701 (NCT07662122), a groundbreaking triple agonist targeting GLP-1, GIP, and the NPY2 receptor, signaling a new direction beyond...
